Compare NIE & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | NIE | TECX |
|---|---|---|
| Founded | 2007 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 726.3M | 618.9M |
| IPO Year | N/A | 2018 |
| Metric | NIE | TECX |
|---|---|---|
| Price | $25.38 | $20.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $71.00 |
| AVG Volume (30 Days) | 90.5K | ★ 232.9K |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | ★ 9.04% | N/A |
| EPS Growth | N/A | ★ 40.70 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.78 | $15.60 |
| 52 Week High | $27.24 | $39.53 |
| Indicator | NIE | TECX |
|---|---|---|
| Relative Strength Index (RSI) | 48.48 | 27.01 |
| Support Level | $25.28 | $20.52 |
| Resistance Level | $25.76 | $30.80 |
| Average True Range (ATR) | 0.35 | 1.23 |
| MACD | 0.09 | 0.07 |
| Stochastic Oscillator | 65.22 | 12.66 |
Virtus AllianzGI Equity & Convertible Income Fund is a diversified, closed-end management investment company. The investment objective is to provide total return through a combination of current income, current gains and long-term capital appreciation. The fund pursues its objective by investing in a diversified portfolio of equity securities and income-producing convertible securities. Its portfolio of investments comprises different sector investments, such as aerospace and defense, banks, IT services, software, and others.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.